Danish Novo Nordisk – which with its successes with weight loss preparations in a few years has become a world-leading pharmaceutical company – is likely to account for half of Denmark's growth this year, according to the economists at the major bank Danske Bank.
Denmark's growth is estimated to be 1.8 percent this year in a fresh prognosis from the bank, a downward adjustment from an earlier estimate of 2.1 percent. The reason the growth will not be as high as previously expected is due to an upward adjustment of the growth in the comparison year 2023.
Besides the significant economic contribution from Novo Nordisk – but also the pharmaceutical company Bavarian Nordic's mpox vaccine – the Danish economy is favored by the fact that the population's purchasing power has not been affected as negatively by the global inflation and interest rate shock as in comparable countries.
Swedish growth this year is estimated to be 1.2 percent, according to Danske Bank's economists. The prognosis for Norway is lowered to 0.7 percent in growth, while Finland's economy is expected to shrink by 0.4 percent.
